AbbVie Rheumatology: Let’s Change Lives

AbbVie has been striving to advance the standard of care in rheumatology for over 20 years. We are committed to creating a better tomorrow for patients everywhere.

A Legacy of Innovation

A deep understanding of rheumatology and immune-mediated disease has long been at the core of AbbVie innovation. More than two decades ago, AbbVie began a robust clinical development program with trials focused on rheumatoid arthritis (RA). Our early research efforts in 1997 led to the development of a revolutionary biologic treatment approved for multiple immune-mediated diseases. Yet our curiosity and dedication remain unyielding. We continue to seek new pathways, uncover new solutions and help patients live the life they want.

Learn more about our Rheumatology priorities >>

Rheumatoid Arthritis (RA)

This chronic, immune-mediated disease causes pain, stiffness, swelling and loss of joint function. RA can reduce patients’ ability to perform everyday tasks.

Juvenile Idiopathic Arthritis (JIA)

Including several forms of chronic arthritis, this immune-mediated disease affects children ages 16 and younger. For patients living with JIA, early diagnosis and treatment are important.

Psoriatic Arthritis (PsA)

This disease associated with psoriasis causes chronic pain, stiffness and swelling in the joints. Early diagnosis is important.

Ankylosing Spondylitis (AS)

A chronic, immune-mediated disease, AS affects the spine. It is more common in men, but women are often underdiagnosed.


This group of eye diseases is characterized by inflammation of the uvea, the middle layer of the eye. If left untreated, uveitis can lead to reduced vision or vision loss.

Systemic lupus erythematosus (SLE)

The most common type of lupus, especially among women of childbearing age, this immune-mediated disease is associated with inflammation of multiple organ systems.

Pioneers in Science

The Road Ahead

Targeted Focus in Rheumatic Diseases

In order to develop targeted therapies, AbbVie scientists have demonstrated an unwavering focus on understanding what makes the immune system turn on patients, causing RA and other immune-mediated diseases. As a result, the new medicines we’re creating target specific enzymes involved in the process. One such investigational asset has advanced to Phase 3 clinical trials.

The Road Ahead

Delivering a One-Two Punch

Immune-mediated diseases are complex and often operate through complementary pathways. We are exploring ways to inhibit multiple disease pathways and enable greater precision through technologies like Antibody Drug Conjugates (ADCs) and combination therapies. First developed for oncology, ADCs have the potential to deliver anti-inflammatory medicine directly to a precise target. Combination therapies may be needed to better combat complex immune-mediated diseases by delivering two therapies in one package.

New Pathways

Real World Impact

To help patients and health care professionals understand and maximize the effectiveness of our medicines in the real world, we investigate their impact outside of clinical trial settings. For example, our PASSION study showed an association between patient support programs and functional outcomes for patients with moderate to severe RA.

Key Pathways


Transmits messages from the outside to the inside of a cell that drive an immune response.
Learn more about related assets in our Pipeline


Activates T cells, which produce additional cytokines that are involved in the inflammatory process.
Learn more about related assets in our Pipeline


Contributes to the induction and maintenance of the inflammatory immune response.
Learn more about related assets in our Pipeline


Activates the production and growth of B cells, which produce antibodies that help the body protect itself.
Learn more about related assets in our Pipeline

Rheumatology at AbbVie

In the News

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients
Read More

Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis
Read More

Join Our Team

Our team of Rheumatology experts is focused on improving the standard of care for this generation and the next. We’re pioneers, builders and innovators; and we’re hiring.


What Makes the Immune System Compromise Your Health?
JAK enzymes can be responsible for inappropriate activation of immune cells that play a critical role in autoimmune disorders.

Get the Latest from AbbVie

Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.

This site uses cookies to personalize content, save your preferences and track the site’s performance. Learn more, including how to disable certain cookies on our Privacy Page. Click OK to continue.